3 Stocks That Soared Stupendously This Week презентация

set the pace. Here are three that soared by 25% and more.

1

2

3

Bio (Nasdaq:BLUE)

Source: Yahoo! Finance

study of LentiGlobin in treating beta-thalassemia, a rare genetic blood disorder
The first two patients in the study were blood transfusion independent as of day 10 and 12, respectively with no drug-related adverse events, according to the company
This marks very encouraging news for Bluebird, which also has a couple of other mid-stage studies underway for LentiGlobin
It’s also potentially good news for the estimated 228,000 patients suffering from the rare disease

Why Bluebird Bio shares flew

Insmed (Nasdaq:INSM)

Source: Yahoo! Finance

The drug targets treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease who are treatment refractory
Breakthrough status designation stemmed from the company’s phase 2 study of Arikayce, which produced some positive results even though the primary endpoint wasn’t met
Insmed reported good results last year from a phase 3 study of Arikayce conducted in Europe and Canada targeting treatment of lung infection in cystic fibrosis patients

Why Insmed shares ignited

Covidien (NYSE:COV)

Source: Yahoo! Finance

for $42.9 billion
The deal expands Medtronic’s product lineup and should produce $850 million of annual cost synergies by 2018
It also helps significantly on the tax front, with Medtronic moving to tax-friendly Ireland, where Covidien is currently based

Why Covidien shares crushed the market

much more now
Further good news for Arikayce would keep positive momentum going for Insmed
The best pick for continuing the winning ways, though, appears to be Bluebird Bio
While the data is still early for LentiGlobin, it’s also very promising
Bluebird stands a solid chance to keep flapping its wings higher

Best pick to keep soaring?

?

as the top pick for 2014 in our free report!